Generation of Dendritic Cell Precursors From Cord Blood Stem Cells

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00731744
First received: August 7, 2008
Last updated: August 8, 2008
Last verified: August 2008
  Purpose

There is a growing interest in generating dendritic cells (DCs) for using as vaccines. Several cytokines, especially stem cell factor (SCF) and FLT3-ligand (FL), have been identified as essential to produce large numbers of myeloid precursors and even to increase DC yield obtained by the action of granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor alpha (TNF-α). However, there are few studies on the effect of the early-acting cytokines, commonly used to expand CD34+ progenitor cells, on DC generation.

We have established a serious of functional analysis of maturated or immaturated DCs including surface markers screening or cytokine production. Here, we design this two-year project to evaluate the possible methodology in the generation of CD14+CD1a- and CD14- CD1a+ myeloid DC precursors from CD34+ cells. In the first year of the project, we will set up the standard protocol to generate DC precursors from cord blood stem cells. In the first step, we will isolate CD34+ cells from cord blood and amplify these cells. Purity of the CD34+ cell populations obtained will be greater than 90%. In the next step, these primary cultures of CD34+ cells will treat with early-acting cytokines such as GM-CSF and IL-4 to further induction into dendritic cells. Functional analysis of dendritic cells would be performed in this stage. In the second year of the project, we will further evaluate the induction of DCs by CD34+ stem cells could be affected by combination of mesenchymal stromal cells. These results of this research with CD34+-based DCs induction provide the basis for materials to develop the DC-based vaccine against viral and fungal infections, and might be a powerful tool in anti-tumor immunotherapy.


Condition Intervention
Normal Full-Term Deliveries
Procedure: Normal full-term deliveries

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Generation of Dendritic Cell Precursors From Cord Blood Stem Cells

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • None, we isolate stem cells from cord blood. [ Time Frame: from CS operation to close ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: January 2007
Estimated Study Completion Date: December 2010
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Normal full-term deliveries
    Normal full-term deliveries by standard procedures according to institutional guidelines
  Eligibility

Ages Eligible for Study:   25 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Normal full-term deliveries

Exclusion Criteria:

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00731744

Contacts
Contact: Chien-Nan Lee, Associate Professor 886-2-23123456 ext 5166 leecn@ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Chien-Nan Lee, ASSOCIATE PROFESSOR    886-2-23123456 ext 5166    leecn@ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: Chien-Nan Lee, National Taiwan Unviersity Hospital
ClinicalTrials.gov Identifier: NCT00731744     History of Changes
Other Study ID Numbers: 200706003R
Study First Received: August 7, 2008
Last Updated: August 8, 2008
Health Authority: Taiwan: Department of Health

ClinicalTrials.gov processed this record on April 15, 2014